•
Dec 31, 2019

Glaukos Q4 2019 Earnings Report

Glaukos reported strong Q4 2019 results with a 22% increase in net sales, driven by Glaucoma unit volume increases and the Avedro acquisition.

Key Takeaways

Glaukos Corporation announced its Q4 and full year 2019 financial results, highlighted by a 22% increase in net sales for the quarter, reaching $65.8 million. The growth was fueled by increased Glaucoma unit volume and the contribution from the Avedro acquisition. The company introduced 2020 net sales guidance of $290 million to $300 million.

Net sales increased by 22% to $65.8 million compared to Q4 2018.

Glaucoma net sales grew by 11% to $59.8 million compared to Q4 2018.

Corneal Health net sales reached $6.0 million from November 21, 2019, through December 31, 2019, following the Avedro acquisition.

The company provided 2020 net sales guidance of $290 million to $300 million.

Total Revenue
$65.8M
Previous year: $54.1M
+21.8%
EPS
-$0.06
Previous year: $0.04
-250.0%
Gross margin
76%
Previous year: 87%
-12.6%
Non-GAAP gross margin
85%
Previous year: 87%
-2.3%
SG&A expenses
$59.6M
Previous year: $32.1M
+85.7%
Gross Profit
$49.9M
Previous year: $47M
+6.4%
Cash and Equivalents
$62.4M
Previous year: $29.8M
+109.3%
Free Cash Flow
-$5.39M
Previous year: $9.55M
-156.4%
Total Assets
$818M
Previous year: $207M
+295.4%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2020 net sales to be in the range of $290 to $300 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income